[go: up one dir, main page]

AR113881A1 - Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia - Google Patents

Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia

Info

Publication number
AR113881A1
AR113881A1 ARP180103328A ARP180103328A AR113881A1 AR 113881 A1 AR113881 A1 AR 113881A1 AR P180103328 A ARP180103328 A AR P180103328A AR P180103328 A ARP180103328 A AR P180103328A AR 113881 A1 AR113881 A1 AR 113881A1
Authority
AR
Argentina
Prior art keywords
methods
compositions
treatment
immune disorders
blautia strain
Prior art date
Application number
ARP180103328A
Other languages
English (en)
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of AR113881A1 publication Critical patent/AR113881A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Se proporcionan en el presente métodos y composiciones relacionados con la cepa A de Blautia útiles como agentes terapéuticos.
ARP180103328A 2017-11-14 2018-11-14 Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia AR113881A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762585782P 2017-11-14 2017-11-14

Publications (1)

Publication Number Publication Date
AR113881A1 true AR113881A1 (es) 2020-06-24

Family

ID=64746632

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103328A AR113881A1 (es) 2017-11-14 2018-11-14 Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia

Country Status (7)

Country Link
US (2) US10493113B2 (es)
EP (1) EP3710023A1 (es)
JP (1) JP2021502964A (es)
CN (1) CN111601610A (es)
AR (1) AR113881A1 (es)
TW (1) TW201936203A (es)
WO (1) WO2019099482A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117959415A (zh) 2016-09-13 2024-05-03 阿勒根公司 非蛋白质梭菌毒素组合物
JP7542946B2 (ja) 2016-09-27 2024-09-02 ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
WO2019046401A1 (en) * 2017-08-29 2019-03-07 Evelo Biosciences, Inc. TREATMENT OF CANCER USING BLAUTIA STRAIN
EP3710023A1 (en) 2017-11-14 2020-09-23 Evelo Biosciences, Inc. Compositions and methods for treating disease using a blautia strain
CN111712260A (zh) * 2018-01-31 2020-09-25 伊夫罗生物科学公司 使用毛螺菌科细菌治疗免疫病症的组合物和方法
SG11202100023XA (en) * 2018-07-11 2021-01-28 Actym Therapeutics Inc Engineered immunostimulatory bacterial strains and uses thereof
WO2020150429A1 (en) * 2019-01-16 2020-07-23 Board Of Regents, The University Of Texas System Methods and compositions for treating immune checkpoint inhibitor associated colitis
AU2020276670A1 (en) * 2019-05-10 2021-12-09 4D Pharma Research Limited Compositions comprising bacterial strains
KR20220020893A (ko) * 2019-06-11 2022-02-21 에벨로 바이오사이언시즈, 인크. 분비된 미생물 세포외 소포
CN112442455B (zh) * 2019-09-03 2022-04-01 北京量化健康科技有限公司 具有防治高血脂症功能的布劳特氏菌以及产品组合物及其制备方法和应用
CN111304120B (zh) * 2020-02-24 2021-07-23 浙江大学 Blautia sp B2132菌在预防和/或治疗炎症性肠病中的应用
EP4157297A4 (en) * 2020-05-28 2024-04-10 Trench Therapeutics, Inc. Airway medicaments
TW202216178A (zh) * 2020-06-11 2022-05-01 美商艾弗洛生物科技股份有限公司 使用巨型球菌屬物種治療疾病及障礙之組成物及方法
WO2021252838A1 (en) * 2020-06-11 2021-12-16 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using fournierella massiliensis
JP2023530413A (ja) * 2020-06-11 2023-07-18 エヴェロ バイオサイエンシズ，インコーポレーテッド オシロスピラ（Ｏｓｃｉｌｌｏｓｐｉｒａｃｅａｅ）微生物細胞外小胞を使用して疾患及び障害を治療するための組成物及び方法
CN113842497B (zh) * 2021-09-28 2022-05-17 太原理工大学 一种具有光控抗菌和自愈合功能的CuS@Cur杂化水凝胶敷料的制备方法
CN114225024B (zh) * 2021-12-29 2022-08-19 山东健袖生态科技有限公司 一种用于治疗疾病的益生菌药物
EP4494484A1 (en) 2022-03-18 2025-01-22 Meiji Co., Ltd Collinsella bacteria proliferation controlling composition and use thereof
WO2023192360A1 (en) * 2022-03-31 2023-10-05 Incelldx, Inc. Methods of treating a subject for post-treatment lyme disease (ptld) and compositions for use in the same
US20250235433A1 (en) * 2022-04-19 2025-07-24 Cedars-Sinai Medical Center Methods of treating and diagnosing fatty liver disease
CN114806979A (zh) * 2022-06-29 2022-07-29 杭州师范大学附属医院(杭州市第二人民医院) 一种治疗非酒精性脂肪性肝病的益生菌复合物及其应用
CN116254198B (zh) * 2023-01-05 2024-03-26 中国科学院微生物研究所 一种布劳特氏菌及其应用
CN116549465B (zh) * 2023-04-26 2025-02-11 复旦大学附属中山医院 Aldh2小分子激动剂在制备治疗心血管疾病及其代谢性疾病的药物中的应用
WO2025070283A1 (ja) * 2023-09-25 2025-04-03 オルト株式会社 ブラウティア属細菌を用いた免疫賦活剤
WO2025070280A1 (ja) * 2023-09-25 2025-04-03 オルト株式会社 ブラウティア属細菌
JP7706191B2 (ja) * 2023-09-25 2025-07-11 オルト株式会社 ブラウティア属細菌を用いた免疫賦活剤
JP7706190B2 (ja) * 2023-09-25 2025-07-11 オルト株式会社 ブラウティア属細菌
CN117617181B (zh) * 2023-12-27 2025-10-28 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种系统性红斑狼疮小鼠模型的构建方法和应用
CN119709558B (zh) * 2025-02-26 2025-05-30 昆明医科大学第一附属医院(云南省皮肤病医院) 布劳特氏菌emf75-02b1b及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
WO2014201037A2 (en) * 2013-06-10 2014-12-18 New York University Methods for manipulating immune responses by altering microbiota
FI3223835T3 (fi) * 2014-11-25 2025-06-16 Memorial Sloan Kettering Cancer Center Suolen mikrobisto ja gvhd
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US9492473B2 (en) * 2015-01-26 2016-11-15 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
SI3285777T1 (sl) * 2015-04-23 2022-02-28 Kaleido Biosciences, Inc. Glikanski terapevtiki in postopki zdravljenja
SG10201912323VA (en) * 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2017035188A1 (en) * 2015-08-24 2017-03-02 Nubyiota Llc Systems and methods for treating a dysbiosis using fecal-derived bacterial populations
CN107083339B (zh) * 2017-03-01 2020-02-14 华中农业大学 防治仔猪腹泻的复合益生菌制剂及其制备方法和应用
EP3710023A1 (en) * 2017-11-14 2020-09-23 Evelo Biosciences, Inc. Compositions and methods for treating disease using a blautia strain

Also Published As

Publication number Publication date
JP2021502964A (ja) 2021-02-04
US10493113B2 (en) 2019-12-03
WO2019099482A1 (en) 2019-05-23
US20200030389A1 (en) 2020-01-30
EP3710023A1 (en) 2020-09-23
US10702561B2 (en) 2020-07-07
US20190216862A1 (en) 2019-07-18
TW201936203A (zh) 2019-09-16
CN111601610A8 (zh) 2023-07-21
CN111601610A (zh) 2020-08-28

Similar Documents

Publication Publication Date Title
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
CO2020007142A2 (es) Composiciones y métodos para el tratamiento de los trastornos inmunitarios utilizando cepas de bacterias inmunomoduladoras de lactococcus
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
EA201691582A1 (ru) Новые фармацевтические препараты
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
GT201700072A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MX2017005030A (es) Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio.
MX2018006637A (es) Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CR20170060A (es) Anticuerpos anti tigit
MX2017001279A (es) Usos y composiciones de la flagelina.
MX2021015632A (es) Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
EA201991997A1 (ru) Комбинированная терапия
NZ743049A (en) Anti-cd3-folate conjugates and their uses
MX2018012230A (es) Métodos para tratar enfermedades oculares.
MX395492B (es) Usos terapeuticos de l-4 cloroquinurenina.
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
MX2019008460A (es) Metodos para tratar esclerosis multiple usando celulas t autologas.
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.

Legal Events

Date Code Title Description
FB Suspension of granting procedure